Skip to Content

United Therapeutics Corp UTHR Stock Quote

| Rating as of


Morningstar‘s Stock Analysis UTHR

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


United Therapeutics Reports Q3 Results in Line with Expectations; Maintaining $213 FVE

Rachel Elfman Equity Analyst

Analyst Note

| Rachel Elfman |

United Therapeutics reported solid third-quarter results in line with our expectations, and its pipeline is continuing to progress in development. Total revenue for the quarter was $516 million, representing a 16% increase year over year. We maintain our fair value estimate of $213 per share, and our no-moat, stable moat trend, and High Uncertainty Ratings. We view shares as overvalued, currently trading in 2-star territory.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics UTHR

Company Profile UTHR

Business Description

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

1040 Spring Street
Silver Spring, MD, 20910
T +1 301 608-9292
Industry Biotechnology
Most Recent Earnings Sep 30, 2022
Fiscal Year End Dec 31, 2022
Employees 965